Advanced Medical Solutions Group Plc · LSE:AMS
Advanced Medical Solutions — Shareholder Meeting (June 2019)
6 slides from Advanced Medical Solutions's shareholder meeting presentation, Jun 5, 2019
Slide 1: Annual General Meeting
Advanced Medical Solutions Group plc Annual General Meeting Chris Meredith Chief Executive Officer 5th June 2019
Slide 2: FY 2018 Highlights (incl. post period end)
Advanced Medical Solutions Group plc 1 FY 2018 Highlights (incl. post period end) • Group revenues up 7% at constant currency to £102.6m and up 6% at reported currency • Adjusted operating margin improvement of 180 basis points to 28.0% (2017 FY: 26.2%) • Branded performing well, marginally offset b
Slide 3: Acquisition of Sealantis
Advanced Medical Solutions Group plc 2 Acquisition of Sealantis • Acquisition in January 2019 for $25m (c. £19m), plus royalty agreement • Internal sealants market over $1.0 billion and growing • Brings a significant pipeline of products, intellectual property, and an outstanding R&D team • The most
Slide 4: Internal sealants and fixation devices portfolio strengthened by acquisition of Sealantis
Advanced Medical Solutions Group plc 3 Internal sealants and fixation devices portfolio strengthened by acquisition of Sealantis Intended for use in laparoscopic & open surgical repair of inguinal and ventral hernias, achieved >$0.5bn through the fixation of prosthetic mesh to the abdominal wall, ap
Slide 5: AMS broadens its opportunities in the combined >$3.3bn Fixation, Sealants & Haemostats market
Advanced Medical Solutions Group plc 4 AMS broadens its opportunities in the combined >$3.3bn Fixation, Sealants & Haemostats market 1200 >$0.5bn Fixation 1000 >$1bn Thrombin >$900m Haemostats Sealants Market Size ($m) 800 >$3.3bn 600 >$600m Fibrin Sealants Fixation, Sealants & Fixation >$500m Haemo
Slide 6: Significant clinical need and platform technology advantages strengthen the Sealantis proposition
Advanced Medical Solutions Group plc 5 Significant clinical need and platform technology advantages strengthen the Sealantis proposition Significant Clinical Need Gastrointestinal leakage is associated with high rates of post-op complications, >$0.5bn cost, re-operation & mortality2 Fixation >$1bn 9
Advanced Medical Solutions Group — Shareholder Meeting (June 2019) on 6ix